All studies
Not yet recruitingPhase IInterventional

A clinical study investigating whether it is safe to give children with newly diagnosed pontine diffuse midline glioma a drug called MTX110 using a device that helps deliver the drug directly to the tumour in the brain

Pontine diffuse midline glioma is a serious childhood brain tumour that grows deep inside the brainstem. Because of its location, surgery cannot remove it. Standard chemotherapy also struggles to reach the tumour due to the brain's natural protective barriers. This trial investigates a drug called MTX110. Instead of giving it by mouth or through a vein, surgeons place four very thin tubes directly into the tumour, connected to a small port under the scalp. This allows the medicine to be delivered straight to the cancer cells. The main aim of this Phase I study is to see if giving regular doses of MTX110 every two to three weeks after radiotherapy is safe and feasible. Researchers also want to find out if this targeted treatment can help children live longer. The study is managed by UCL and Cancer Research UK.

At a glance

Status
Not yet recruiting
Phase
Phase I
Sponsor
University College London
Enrolment target
9
Start
01 Jan 2027
Estimated completion
01 Jan 2030

What is this study about?

Pontine diffuse midline glioma (sometimes called DIPG) is an aggressive brain tumour that affects children. It develops in the pons, a part of the brainstem that controls essential body functions such as breathing, heart rate, and swallowing. Because it is tangled within healthy, vital brain tissue, surgeons cannot safely cut the tumour away. Radiotherapy is the standard treatment to help shrink the tumour and relieve symptoms, but its effects are usually temporary. Traditional chemotherapy has had little success because the body's natural blood-brain barrier stops most medicines from reaching the brainstem.

To overcome this barrier, researchers are testing a technique called convection-enhanced delivery using the NeuroChase Drug Delivery System. A neurosurgeon places four hair-thin tubes (catheters) directly into the tumour using detailed scans for guidance. These tubes link to a small access port sitting just under the skin. This setup allows doctors to pump a targeted cancer drug called MTX110 straight into the tumour, bypassing the protective barrier and reducing drug exposure to the rest of the body.

An earlier study in the United States showed encouraging results, finding that this direct delivery method was workable and that children receiving MTX110 lived longer than usually expected. This new UK trial hopes to build on those findings by testing repeated infusions given every two to three weeks after initial radiotherapy, checking carefully for safety, side effects, and overall benefit.

Key takeaways

  • Tests a direct-to-tumour delivery method for a drug called MTX110 in children with pontine DMG.
  • Bypasses the brain's protective blood-brain barrier using four hair-thin implanted tubes.
  • Aimed at children aged 3 to 16 with newly diagnosed tumours who have had radiotherapy.
  • Focuses primarily on safety, finding the best dosing schedule, and monitoring survival.
  • Participation is entirely voluntary and run through specialist UK children's cancer centres.

Who may be eligible?

This trial is open to children and young people aged between 3 and 16 years who have recently been diagnosed with a diffuse midline glioma located in the pons. The tumour must have a specific genetic change known as H3K27M, which is confirmed through a biopsy, and must be clearly visible on an MRI scan covering at least two-thirds of the pons.

To join, participants must have started standard external beam radiotherapy to the brainstem within two to three weeks of their diagnosis. If they take steroid medicines (such as dexamethasone) to control brain swelling, their dose must be stable or decreasing for at least a week before joining.

Children must also be well enough to cope with the procedures. This means they must have adequate kidney, liver, and bone marrow function, shown through blood tests. They must be able to have general anaesthesia, CT scans, and MRI scans with contrast dye. Children cannot take part if they have metal implants that prevent MRI scans, or if brain scans show bleeding or fluid cysts that block the path for the delivery tubes.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Child is aged between 3 and 16 years old
  2. Newly diagnosed with a pontine diffuse midline glioma (H3K27M altered)
  3. Has started standard external beam radiotherapy within 2 to 3 weeks of diagnosis
  4. Able to have general anaesthesia, MRI scans, and CT scans safely
  5. Steroid medication (dexamethasone) dose is stable or decreasing
  6. Blood tests show satisfactory liver, kidney, and bone marrow function
Answer every question to see your result.

What does participation involve?

Taking part begins with a surgical procedure under general anaesthesia to place the tiny delivery tubes and port into the brain. Once the system is in place and radiotherapy is complete, your child will receive infusions of MTX110 directly through the port every 2 to 3 weeks. Each infusion requires a hospital visit. The care team will closely monitor your child using regular MRI scans, blood tests, neurological checks, and general health reviews to track their progress and watch for any side effects. Treatment continues until the tumour shows signs of growing or if side effects become unmanageable. The overall study is scheduled to run from 2027 to 2032.

Potential risks and benefits

The potential benefit of joining this study is receiving an innovative treatment that targets the tumour directly, which may help slow tumour growth and extend survival. However, because this is an early-phase trial, direct benefit cannot be guaranteed. Risks include surgical complications from placing the tubes (such as infection, bleeding, or fluid leakage) and side effects caused by the drug MTX110 itself. Having regular scans and hospital visits can also be tiring for children and families. Taking part is completely voluntary, and you can withdraw your child from the trial at any point without it affecting their normal NHS care.

Locations (1)

  • Great Ormond Street Hospital for Children
    Approximate
    London, England

Common questions

What is the main purpose of this Phase I trial?

The main goal is to test whether giving MTX110 directly into the brain tumour using a special tube system is safe, practical, and well-tolerated by children.

Does my child still receive standard radiotherapy?

Yes. Radiotherapy remains a core part of treatment. Children must start their standard radiotherapy within 2 to 3 weeks of diagnosis before moving on to the trial infusions.

How is the drug actually given?

A surgeon implants four tiny tubes into the tumour connected to a small port under the skin. The medicine is then infused slowly through this port directly into the tumour.

Will taking part require a hospital stay?

Your child will need a short stay in hospital for the surgery to place the delivery system. After that, infusions are given during regular hospital visits every 2 to 3 weeks.

Can we leave the study if we change our minds?

Yes. You have the right to withdraw your child from the study at any time, for any reason, without giving up any standard medical care or support from your hospital team.

How to find out more

DELIVERY Trial Manager

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A clinical study investigating whether it is safe to give ch…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.